Novartis Dismissed Drugs' Link To Bone Death, Doc Testifies

Law360, New York (April 29, 2013, 10:17 PM EDT) -- A medical expert for a woman suing Novartis Pharmaceuticals Corp. in New Jersey mass tort litigation over its bone drug Zometa told jurors Monday the company was loath to acknowledge the drug could lead to jaw bone death after cases began surfacing.

Attorneys for plaintiff Beverly Meng called the chief of the Division of Oral and Maxillofacial Surgery at the University of Miami School of Medicine to testify on Zometa and its less potent predecessor Aredia, which are part of a class of drugs known as bisphosphonates....
To view the full article, register now.